메뉴 건너뛰기




Volumn 10, Issue 6, 2011, Pages 987-996

Gefitinib for non-small-cell lung cancer treatment

Author keywords

EGFR; Gefitinib; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; MUTANT PROTEIN; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE;

EID: 80054759817     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.617738     Document Type: Review
Times cited : (11)

References (49)
  • 2
    • 65349116059 scopus 로고    scopus 로고
    • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial
    • FLEX Study Team
    • Pirker R, Pereira JR, Szczesna A, et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31
    • (2009) Lancet , vol.373 , pp. 1525-31
    • Pirker, R.1    Pereira, J.R.2    Szczesna, A.3
  • 3
    • 77949886293 scopus 로고    scopus 로고
    • Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
    • Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:918-27
    • (2010) J Clin Oncol , vol.28 , pp. 918-27
    • Khambata-Ford, S.1    Harbison, C.T.2    Hart, L.L.3
  • 7
    • 0034068319 scopus 로고    scopus 로고
    • Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor- selective tyrosine kinase inhibitor
    • Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63 (Pubitemid 30305105)
    • (2000) Clinical Cancer Research , vol.6 , Issue.5 , pp. 2053-2063
    • Ciardiello, F.1    Caputo, R.2    Bianco, R.3    Damiano, V.4    Pomatico, G.5    De Placido, S.6    Bianco, A.R.7    Tortora, G.8
  • 8
    • 18244371651 scopus 로고    scopus 로고
    • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    • Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:225-35
    • (2005) PLoS Med , vol.2 , pp. 225-35
    • Pao, W.1    Miller, V.A.2    Politi, K.A.3
  • 10
    • 0035023187 scopus 로고    scopus 로고
    • Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
    • Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001;40:297-306 (Pubitemid 32458155)
    • (2001) Clinical Pharmacokinetics , vol.40 , Issue.4 , pp. 297-306
    • Swaisland, H.1    Laight, A.2    Stafford, L.3    Jones, H.4    Morris, C.5    Dane, A.6    Yates, R.7
  • 11
    • 33745899929 scopus 로고    scopus 로고
    • Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics
    • DOI 10.2165/00003088-200645060-00006
    • Swaisland HC, Cantarini MV, Fuhr R, et al. Exploring the relationship between expression of cytocrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 2006;45:633-44 (Pubitemid 44046489)
    • (2006) Clinical Pharmacokinetics , vol.45 , Issue.6 , pp. 633-644
    • Swaisland, H.C.1    Cantarini, M.V.2    Fuhr, R.3    Holt, A.4
  • 12
    • 25144436285 scopus 로고    scopus 로고
    • Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol
    • Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005;44:1076-81
    • (2005) Clin Pharmacokinet , vol.44 , pp. 1076-81
    • Swaisland, H.C.1    Ranson, M.2    Smith, R.P.3
  • 15
    • 4143110253 scopus 로고    scopus 로고
    • Gefitinib in patients with brain metastasesfrom non-small-cell lung cancer: A prospective trial
    • DOI 10.1093/annonc/mdh276
    • Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004;15:1042-7 (Pubitemid 39089780)
    • (2004) Annals of Oncology , vol.15 , Issue.7 , pp. 1042-1047
    • Ceresoli, G.L.1    Cappuzzo, F.2    Gregorc, V.3    Bartolini, S.4    Crino, L.5    Villa, E.6
  • 16
    • 4944226682 scopus 로고    scopus 로고
    • Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
    • DOI 10.1016/j.lungcan.2004.04.036, PII S0169500204002144
    • Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004;46:255-61 (Pubitemid 39330419)
    • (2004) Lung Cancer , vol.46 , Issue.2 , pp. 255-261
    • Hotta, K.1    Kiura, K.2    Ueoka, H.3    Tabata, M.4    Fujiwara, K.5    Kozuki, T.6    Okada, T.7    Hisamoto, A.8    Tanimoto, M.9
  • 20
    • 52049096854 scopus 로고    scopus 로고
    • Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE) a randomized, phase II study
    • Crino L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE) a randomized, phase II study. J Clin Oncol 2008;26:4253-60
    • (2008) J Clin Oncol , vol.26 , pp. 4253-60
    • Crino, L.1    Cappuzzo, F.2    Zatloukal, P.3
  • 21
    • 65549154268 scopus 로고    scopus 로고
    • Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status
    • Goss G, Ferry D, Laurie S, et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253-60
    • (2009) J Clin Oncol , vol.27 , pp. 2253-60
    • Goss, G.1    Ferry, D.2    Laurie, S.3
  • 22
    • 33646867322 scopus 로고    scopus 로고
    • Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
    • DOI 10.1097/01.cad.0000203381.99490.ab, PII 0000181320060400000005
    • Cufer T, Vrdoljak E, Gaafar R, et al. SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer. Anticancer Drugs 2006;17:401-9 (Pubitemid 44309982)
    • (2006) Anti-Cancer Drugs , vol.17 , Issue.4 , pp. 401-409
    • Cufer, T.1    Vrdoljak, E.2    Gaafar, R.3    Erensoy, I.4    Pemberton, K.5
  • 25
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomized phase III trial
    • Kim ES, Hirsch V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008;372:1809-18
    • (2008) Lancet , vol.372 , pp. 1809-18
    • Kim, E.S.1    Hirsch, V.2    Mok, T.3
  • 26
    • 52049125250 scopus 로고    scopus 로고
    • Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
    • Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52
    • (2008) J Clin Oncol , vol.26 , pp. 4244-52
    • Maruyama, R.1    Nishiwaki, Y.2    Tamura, T.3
  • 27
    • 76749154617 scopus 로고    scopus 로고
    • Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy
    • Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-14
    • (2010) Clin Cancer Res , vol.16 , pp. 1307-14
    • Lee, D.H.1    Park, K.2    Kim, J.H.3
  • 28
    • 76649144669 scopus 로고    scopus 로고
    • Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials
    • Shepherd FA, Douillard J, Fukuoka M, et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. J Clin Oncol 2009;27(Suppl):S15
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • Shepherd, F.A.1    Douillard, J.2    Fukuoka, M.3
  • 29
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • DOI 10.1016/S0140-6736(05)67625-8, PII S0140673605676258
    • Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37 (Pubitemid 41540110)
    • (2005) Lancet , vol.366 , Issue.9496 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3    Pereira, J.R.4    Ciuleanu, T.5    Von Pawel, J.6    Thongprasert, S.7    Tan, E.H.8    Pemberton, K.9    Archer, V.10    Carroll, K.11
  • 32
    • 33746789922 scopus 로고    scopus 로고
    • Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
    • DOI 10.1200/JCO.2005.05.4692
    • Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6 (Pubitemid 46638887)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.21 , pp. 3340-3346
    • Inoue, A.1    Suzuki, T.2    Fukuhara, T.3    Maemondo, M.4    Kimura, Y.5    Morikawa, N.6    Watanabe, H.7    Saijo, Y.8    Nukiwa, T.9
  • 36
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
    • (2009) N Engl J Med , vol.361 , pp. 947-57
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 37
    • 72449160988 scopus 로고    scopus 로고
    • A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung
    • Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009;4(Suppl):PRS.4
    • (2009) J Thorac Oncol , vol.4 , Issue.SUPPL.
    • Lee, J.S.1    Park, K.2    Kim, S.W.3
  • 38
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
    • Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
    • (2010) Lancet Oncol , vol.11 , pp. 121-8
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3
  • 39
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • North-East Japan Study Group
    • Maemondo M, Inoue A, Kobayashi K, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
    • (2010) N Engl J Med , vol.362 , pp. 2380-8
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3
  • 40
    • 8344230861 scopus 로고    scopus 로고
    • Gefitinib: A review of its use in the management of advanced non-small-cell lung cancer
    • DOI 10.2165/00003495-200464210-00008
    • Frampton JE, Easthope SE. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. Drugs 2004;64:2475-92 (Pubitemid 39480702)
    • (2004) Drugs , vol.64 , Issue.21 , pp. 2475-2492
    • Frampton, J.E.1    Easthope, S.E.2
  • 41
    • 10644261471 scopus 로고    scopus 로고
    • Overview of the tolerability of gefitinib (IRESSA™) monotherapy: Clinical experience in non-small-cell lung cancer
    • DOI 10.2165/00002018-200427140-00002
    • Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 2004;27:1081-92 (Pubitemid 39647851)
    • (2004) Drug Safety , vol.27 , Issue.14 , pp. 1081-1092
    • Forsythe, B.1    Faulkner, K.2
  • 43
    • 33745006872 scopus 로고    scopus 로고
    • Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
    • DOI 10.1200/JCO.2005.04.9866
    • Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung Disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56 (Pubitemid 46630633)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.16 , pp. 2549-2556
    • Ando, M.1    Okamoto, I.2    Yamamoto, N.3    Takeda, K.4    Tamura, K.5    Seto, T.6    Ariyoshi, Y.7    Fukuoka, M.8
  • 44
    • 28444432176 scopus 로고    scopus 로고
    • The results of gefitinib prospective investigation
    • Yoshida S. The results of gefitinib prospective investigation. Med Drug J 2005;41:772-89
    • (2005) Med Drug J , vol.41 , pp. 772-89
    • Yoshida, S.1
  • 45
    • 84857647336 scopus 로고    scopus 로고
    • Iressa: Summary of product characteristics
    • Avalaible from [Last accessed 7 August 2009]
    • Iressa: summary of product characteristics. European Medicines Agency. Avalaible from http://www.emea.europa.eu/humandocs/PDFs/EPAR/iressa/emea- combined-h-1016-en.pdf [Last accessed 7 August 2009]
    • European Medicines Agency
  • 46
    • 63049132774 scopus 로고    scopus 로고
    • North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
    • Inoue A, Kobayashi K, Usui K, et al. North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-400
    • (2009) J Clin Oncol , vol.27 , pp. 1394-400
    • Inoue, A.1    Kobayashi, K.2    Usui, K.3
  • 47
    • 79954606282 scopus 로고    scopus 로고
    • Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations
    • Zhou C, Wu YL, Chen G, et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann Oncol 2010;21(Suppl):LBA13
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL.
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3
  • 48
    • 80053561215 scopus 로고    scopus 로고
    • Spanish Lung Cancer Group; Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial
    • Rosell R, Gervais R, Vergnenegre A, et al. Spanish Lung Cancer Group; Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011;29(Suppl):7503
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. , pp. 7503
    • Rosell, R.1    Gervais, R.2    Vergnenegre, A.3
  • 49
    • 80054731248 scopus 로고    scopus 로고
    • Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804)
    • Zhang L, Shenglin M, Song X, et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J Clin Oncol 2011;29(Suppl):LBA7511
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Zhang, L.1    Shenglin, M.2    Song, X.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.